Systematic gene therapy derived from an investigative study of AAV2/8 vector gene therapy for Fabry disease
Open Access
- 5 September 2023
- journal article
- research article
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 18 (1) , 1-13
Abstract
Background: Fabry disease (FD) is a progressive multisystemic disease characterized by a lysosomal enzyme deficiency. A lack of α-galactosidase A (α-Gal A) activity results in the progressive systemic accumulation of its substrates, including globotriaosylceramide (Gb3) and globotriaosylsphingosine (Lyso-Gb3), which results in renal, cardiac, and/or cerebrovascular disease and early death. Enzyme replacement therapy (ERT) is the current standard of care for FD; however, it has important limitations, including a low half-life, limited distribution, and requirement of lifelong biweekly infusions of recombinant enzymes. Methods: Herein, we evaluated a gene therapy approach using an episomal adeno-associated viral 2/8 (AAV2/8) vector that encodes the human GLA cDNA driven by a liver-specific expression cassette in a mouse model of FD that lacks α-Gal A activity and progressively accumulates Gb3 and Lyso-Gb3 in plasma and tissues. Results: A pharmacology and toxicology study showed that administration of AAV2/8-hGLA vectors (AAV2/8-hGLA) in FD mice without immunosuppression resulted in significantly increased plasma and tissue α-Gal A activity and substantially normalized Gb3 and Lyso-Gb3 content. Conclusions: Moreover, the plasma enzymatic activity of α-Gal A continued to be stably expressed for up to 38 weeks and sometimes even longer, indicating that AAV2/8-hGLA is effective in treating FD mice, and that α-Gal A is continuously and highly expressed in the liver, secreted into plasma, and absorbed by various tissues. These findings provide a basis for the clinical development of AAV2/8-hGLA.Keywords
Funding Information
- The National Key R&D Program of China (2018YFA0800603)
- The National Natural Science Foundation of China (81630021, 82100064)
- The Guangdong Innovative Research Team Program (2016ZT06Y432)
- the Startup R&D Funding of Guangdong University of Technology (50010102)
- the Key Research and Development Program of Guangdong Province (2019B020227003)
This publication has 58 references indexed in Scilit:
- Functional Characterisation of Alpha-Galactosidase A Mutations as a Basis for a New Classification System in Fabry DiseasePLOS Genetics, 2013
- Adenovirus-Associated Virus Vector–Mediated Gene Transfer in Hemophilia BNew England Journal of Medicine, 2011
- Systemic Administration of AAV8-α-galactosidase A Induces Humoral Tolerance in Nonhuman Primates Despite Low Hepatic ExpressionMolecular Therapy, 2011
- Sex differences of urinary and kidney globotriaosylceramide and lyso-globotriaosylceramide in Fabry miceJournal of Lipid Research, 2011
- A pharmacogenetic approach to identify mutant forms of α‐galactosidase a that respond to a pharmacological chaperone for Fabry diseaseHuman Mutation, 2011
- Substrate Reduction Augments the Efficacy of Enzyme Therapy in a Mouse Model of Fabry DiseasePLOS ONE, 2010
- Letter to the editorVirchows Archiv, 2008
- Elevated globotriaosylsphingosine is a hallmark of Fabry diseaseProceedings of the National Academy of Sciences, 2008
- Modulation of tolerance to the transgene product in a nonhuman primate model of AAV-mediated gene transfer to liverBlood, 2007
- Induction and role of regulatory CD4+CD25+ T cells in tolerance to the transgene product following hepatic in vivo gene transferBlood, 2007